ethinyl estradiol; segesterone acetate · Mayne Pharma · NDA 209627
Annovera
Earliest generic entry, as listed
21 Jun 2039
Blocked by patent: US 10918649, US 10925882, US 10940157, US 11529308, US 11850251, US 12303518.
Listed patents · 12 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10918649 | product | 21 Jun 2039 |
| US 10925882 | product | 21 Jun 2039 |
| US 10940157 | product | 21 Jun 2039 |
| US 11529308 | product | 21 Jun 2039 |
| US 11850251 | use U-3785 | 21 Jun 2039 |
| US 12303518 | product | 21 Jun 2039 |
| US 10632066 | use U-2786 | 1 Feb 2039 |
| US 10632066 | use U-2787 | 1 Feb 2039 |
| US 10765628 | use U-2787 | 1 Feb 2039 |
| US 10765628 | use U-2786 | 1 Feb 2039 |
| US 10780047 | use U-2786 | 1 Feb 2039 |
| US 10780047 | use U-2787 | 1 Feb 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209627 · 001 · RLD | ring, vaginal | 0.013MG/24HR;0.15MG/24HR | 21 Jun 2039 |